ASCO GU 2020: A Novel GnRH Antagonist Formulation Leads to Undetectable Testosterone for ≥6 Months in an Animal Model
The agent is under investigation in men with advanced prostate cancer.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.